Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 10 years
- Director since
- 2023
10 years of board service in total across 3 boards, counting each seat separately. Longest: 908 Devices Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
LENZ Therapeutics Inc. June 12, 202665.8%
-
Amneal Pharmaceuticals Inc. May 6, 202692.3%
-
Amneal Pharmaceuticals Inc. May 8, 202599.4%
-
908 Devices Inc. June 13, 202480.2%
-
Amneal Pharmaceuticals Inc. May 2, 202499.3%
-
Amneal Pharmaceuticals Inc. May 9, 202385.8%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| May 7, 2026 | Amneal Pharmaceuticals Inc. | Option exercise | +34,819 | — | — |
| Mar 27, 2026 | LENZ Therapeutics Inc. | Open-market purchase | +5,592 | $8.92 | $49,881 |
| Jun 11, 2025 | 908 Devices Inc. | Option exercise | +11,364 | — | — |
| May 5, 2025 | Amneal Pharmaceuticals Inc. | Option exercise | +40,258 | — | — |
| Jun 12, 2024 | 908 Devices Inc. | Option exercise | +7,777 | — | — |
| May 10, 2024 | Amneal Pharmaceuticals Inc. | Option exercise | +76,453 | — | — |
| Feb 22, 2024 | 908 Devices Inc. | Option exercise | +508 | — | — |
| Jun 14, 2023 | 908 Devices Inc. | Option exercise | +4,771 | — | — |
| May 10, 2023 | Amneal Pharmaceuticals Inc. | Option exercise | +80,128 | — | — |
| Feb 22, 2023 | 908 Devices Inc. | Option exercise | +507 | — | — |
Questions about Jeffrey P. George
What boards is Jeffrey P. George on?
Jeffrey P. George sits on the boards of 908 Devices Inc., Amneal Pharmaceuticals Inc. and LENZ Therapeutics Inc.
How long has Jeffrey P. George served on boards?
Our records show at least 10 years of board service across 3 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.